- Home
- GOODN vs GNLX Comparison
GOODN vs GNLX Comparison
Compare GOODN & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOODN | GNLX |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 110.4M |
| IPO Year | 2003 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GOODN | GNLX |
|---|---|---|
| Price | $20.73 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.83 |
| AVG Volume (30 Days) | 3.7K | ★ 211.2K |
| Earning Date | N/A | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $161,336,000.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $115.89 | ★ N/A |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $20.80 | $2.29 |
| 52 Week High | $23.91 | $8.54 |
Technical Indicators
Market Signals| Indicator | GOODN | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 23.99 | 49.81 |
| Support Level | N/A | $2.51 |
| Resistance Level | $22.67 | $2.93 |
| Average True Range (ATR) | 0.44 | 0.12 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 10.55 | 72.66 |
Price Performance
Historical ComparisonAbout GOODN Gladstone Commercial Corporation
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.